297 related articles for article (PubMed ID: 31112799)
1. Wild type- and mutant p53 proteins in mitochondrial dysfunction: emerging insights in cancer disease.
Blandino G; Valenti F; Sacconi A; Di Agostino S
Semin Cell Dev Biol; 2020 Feb; 98():105-117. PubMed ID: 31112799
[TBL] [Abstract][Full Text] [Related]
2. The cytoplasmic side of p53's oncosuppressive activities.
Comel A; Sorrentino G; Capaci V; Del Sal G
FEBS Lett; 2014 Aug; 588(16):2600-9. PubMed ID: 24747877
[TBL] [Abstract][Full Text] [Related]
3. Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism.
Eriksson M; Ambroise G; Ouchida AT; Lima Queiroz A; Smith D; Gimenez-Cassina A; Iwanicki MP; Muller PA; Norberg E; Vakifahmetoglu-Norberg H
Mol Cell Biol; 2017 Dec; 37(24):. PubMed ID: 28993478
[No Abstract] [Full Text] [Related]
4. Tumor suppressor p53 and its mutants in cancer metabolism.
Liu J; Zhang C; Hu W; Feng Z
Cancer Lett; 2015 Jan; 356(2 Pt A):197-203. PubMed ID: 24374014
[TBL] [Abstract][Full Text] [Related]
5. TP53 mutation, mitochondria and cancer.
Kamp WM; Wang PY; Hwang PM
Curr Opin Genet Dev; 2016 Jun; 38():16-22. PubMed ID: 27003724
[TBL] [Abstract][Full Text] [Related]
6. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
[TBL] [Abstract][Full Text] [Related]
7. New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
Blandino G; Di Agostino S
J Exp Clin Cancer Res; 2018 Feb; 37(1):30. PubMed ID: 29448954
[TBL] [Abstract][Full Text] [Related]
8. Gain-of-function mutant p53 in cancer progression and therapy.
Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53.
Lu P; Vander Mause ER; Redd Bowman KE; Brown SM; Ahne L; Lim CS
J Ovarian Res; 2019 May; 12(1):45. PubMed ID: 31092272
[TBL] [Abstract][Full Text] [Related]
10. Tumor suppressor p53 and metabolism.
Liu J; Zhang C; Hu W; Feng Z
J Mol Cell Biol; 2019 Apr; 11(4):284-292. PubMed ID: 30500901
[TBL] [Abstract][Full Text] [Related]
11. Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis.
Stein Y; Rotter V; Aloni-Grinstein R
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817996
[TBL] [Abstract][Full Text] [Related]
12. Mutant p53-Associated Molecular Mechanisms of ROS Regulation in Cancer Cells.
Cordani M; Butera G; Pacchiana R; Masetto F; Mullappilly N; Riganti C; Donadelli M
Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111081
[TBL] [Abstract][Full Text] [Related]
13. The role of tumor suppressor p53 in metabolism and energy regulation, and its implication in cancer and lifestyle-related diseases.
Hashimoto N; Nagano H; Tanaka T
Endocr J; 2019 Jun; 66(6):485-496. PubMed ID: 31105124
[TBL] [Abstract][Full Text] [Related]
14. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
Stiewe T; Haran TE
Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
[TBL] [Abstract][Full Text] [Related]
15. Mutant p53: an oncogenic transcription factor.
Strano S; Dell'Orso S; Di Agostino S; Fontemaggi G; Sacchi A; Blandino G
Oncogene; 2007 Apr; 26(15):2212-9. PubMed ID: 17401430
[TBL] [Abstract][Full Text] [Related]
16. Mutant p53 in cancer therapy-the barrier or the path.
Zhou X; Hao Q; Lu H
J Mol Cell Biol; 2019 Apr; 11(4):293-305. PubMed ID: 30508182
[TBL] [Abstract][Full Text] [Related]
17. Tid1 is a new regulator of p53 mitochondrial translocation and apoptosis in cancer.
Ahn BY; Trinh DL; Zajchowski LD; Lee B; Elwi AN; Kim SW
Oncogene; 2010 Feb; 29(8):1155-66. PubMed ID: 19935715
[TBL] [Abstract][Full Text] [Related]
18. Mutant p53 and mTOR/PKM2 regulation in cancer cells.
Dando I; Cordani M; Donadelli M
IUBMB Life; 2016 Sep; 68(9):722-6. PubMed ID: 27385486
[TBL] [Abstract][Full Text] [Related]
19. Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer.
Zhang S; Carlsen L; Hernandez Borrero L; Seyhan AA; Tian X; El-Deiry WS
Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454137
[No Abstract] [Full Text] [Related]
20. An overview of the functions of p53 and drugs acting either on wild- or mutant-type p53.
Huang Y; Jiao Z; Fu Y; Hou Y; Sun J; Hu F; Yu S; Gong K; Liu Y; Zhao G
Eur J Med Chem; 2024 Feb; 265():116121. PubMed ID: 38194777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
